PharmaMar annonce que l'étude ATLANTIS a atteint son objectif de recrutement des patients
PR Newswire,
/PRNewswire/ -- L ' étude ATLANTIS sur le traitement du cancer du poumon à petites cellules à la lurbinectine a recruté 600…
/PRNewswire/ -- L ' étude ATLANTIS sur le traitement du cancer du poumon à petites cellules à la lurbinectine a recruté 600…
/PRNewswire/ -- Die ATLANTIS-Studie zu Lurbinectedin bei Patienten mit kleinzelligem Lungenkrebs (SCLC) bezog 600 Patienten in…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
PR Newswire MADRID, August 3, 2018 MADRID, August 3, 2018 /PRNewswire/ -- The U.S.
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
SOURCE PharmaMar MADRID The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for…
/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the…
– PharmaMar (MSE:PHM) ha annunciato oggi che la fase pivotale III dello studio ATLANTIS sul cancro al polmone a piccole cellule…
- PharmaMar (MSE:PHM) ha annunciato oggi che la fase pivotale III dello studio ATLANTIS sul cancro al polmone a piccole cellule…
/PRNewswire/ -- - ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
/PRNewswire/ -- Die ATLANTIS-Studie zu Lurbinectedin bei Patienten mit kleinzelligem Lungenkrebs (SCLC) bezog 600 Patienten in…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
/PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
/PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
/PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
PR Newswire MADRID, July 31, 2018 MADRID, July 31, 2018 /PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
SOURCE PharmaMar MADRID ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160…
/PRNewswire/ -- ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…